Remicade (Infliximab) 100mg is powder for injection used to treat ankylosing spondylitis, rheumatoid arthritis, psoriasis, ulcerative colitis and Crohn’s disease. It works by blocking the action of certain chemical messengers that are responsible for inflammation, swelling and redness associated with certain joint diseases.

Dosage :

Crohn’s Disease

The recommended dose of REMICADE is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active Crohn’s disease or fistulizing Crohn’s disease. For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue REMICADE in these patients.

Ulcerative Colitis

The recommended dose of REMICADE is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adult patients with moderately to severely active ulcerative colitis.

Common side effects are Nausea, Headache, Pain, Sinus inflammation, Upper respiratory tract infection, Infusion reaction, Abdominal pain, Viral infection.

Remicade (Infliximab) 100mg is powder for injection used to treat ankylosing spondylitis, rheumatoid arthritis, psoriasis, ulcerative colitis and Crohn’s disease. It works by blocking the action of certain chemical messengers that are responsible for inflammation, swelling and redness associated with certain joint diseases.

Dosage :

Crohn’s Disease

The recommended dose of REMICADE is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active Crohn’s disease or fistulizing Crohn’s disease. For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue REMICADE in these patients.

Ulcerative Colitis

The recommended dose of REMICADE is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adult patients with moderately to severely active ulcerative colitis.

Common side effects are Nausea, Headache, Pain, Sinus inflammation, Upper respiratory tract infection, Infusion reaction, Abdominal pain, Viral infection.